Clinical Trial Update: Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 study evaluating IMC-A12 (cixutumumab) alone or with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck completed. Result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• IMC-A12 (cixutumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-04-17